Patients can interrupt treatment of immune-supressing medicines for two-weeks in order to boost immunity provided by COVID-19 booster vaccine, finds major study Posted: Wednesday, December 13, 2023 A major clinical trial, supported by researchers at Manchester BRC, has shown that people with inflammatory conditions are able to improve the antibody response from a COVID-19 booster vaccination by interrupting their treatment for two weeks immediately after having the vaccine. Continue reading full article: Patients can interrupt treatment of immune-supressing medicines for two-weeks in order to boost immunity provided by COVID-19 booster vaccine, finds major study
Undifferentiated connective tissue disease – what is it and why is more research needed? Dr Sarah Dyball speaks to Arthritis Digest Posted: Friday, November 10, 2023 For Arthritis Digest magazine, Clinical Research Fellow Dr Sarah Dyball explains what undifferentiated connective tissue disease is and why more research into this condition is needed. Continue reading full article: Undifferentiated connective tissue disease – what is it and why is more research needed? Dr Sarah Dyball speaks to Arthritis Digest
Using digital technologies to forecast and manage chronic pain – Professor John McBeth and Dr Katie Druce speak to Arthritis Digest Posted: Tuesday, September 12, 2023 For Arthritis Digest magazine, Professor John McBeth and Dr Katie Druce highlight how digital technology can forecast and manage chronic pain, which can empower patients living with musculoskeletal disease. Continue reading full article: Using digital technologies to forecast and manage chronic pain – Professor John McBeth and Dr Katie Druce speak to Arthritis Digest
The opioid pendulum: Balancing the risks and benefits – Dr Meghna Jani speaks to Arthritis Digest Posted: Friday, July 7, 2023 For Arthritis Digest magazine, Manchester BRC researcher Dr Meghna Jani discusses balancing the risks and benefits of using opioids to treat pain for people with musculoskeletal conditions. Continue reading full article: The opioid pendulum: Balancing the risks and benefits – Dr Meghna Jani speaks to Arthritis Digest
Transitioning from paediatric to adult rheumatology services – Dr Jenny Humphreys speaks to Arthritis Digest Posted: Thursday, May 25, 2023 For Arthritis Digest magazine, Dr Jenny Humphreys explains what is involved during the transition from adult to paediatric services for people with juvenile idiopathic arthritis. Continue reading full article: Transitioning from paediatric to adult rheumatology services – Dr Jenny Humphreys speaks to Arthritis Digest
Identifying biomarkers to improve treatment outcomes for rheumatoid arthritis patients – Dr Darren Plant speaks to Arthritis Digest Posted: Thursday, March 2, 2023 For Arthritis Digest magazine, Dr Darren Plant explains how the future will see us identify biomarkers to improve rheumatoid arthritis treatment outcomes. Continue reading full article: Identifying biomarkers to improve treatment outcomes for rheumatoid arthritis patients – Dr Darren Plant speaks to Arthritis Digest
Inflammatory arthritis diagnosis from past to present – Professor Anne Barton speaks to Arthritis Digest Posted: Thursday, January 26, 2023 Speaking to Arthritis Digest magazine, Professor Anne Barton explains how a diagnosis of inflammatory arthritis is life changing, but is no longer a life sentence. Continue reading full article: Inflammatory arthritis diagnosis from past to present – Professor Anne Barton speaks to Arthritis Digest
Interrupting the treatment of vulnerable people on immune-suppressing medicines, doubles their antibody response to COVID-19 booster vaccination Posted: Monday, July 11, 2022 A major clinical trial supported by Manchester BRC researchers has found that by interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination, their antibody response to the jab is doubled. Continue reading full article: Interrupting the treatment of vulnerable people on immune-suppressing medicines, doubles their antibody response to COVID-19 booster vaccination